Methotrexate versus combination methotrexate and etanercept for rheumatoid arthritis Aarat M. PatelLarry W. Moreland Clinical Trials Report 06 October 2009 Pages: 309 - 310
Certolizumab pegol in active rheumatoid arthritis Aarat M. PatelLarry W. Moreland Clinical Trials Report 06 October 2009 Pages: 311 - 312
Tocilizumab versus methotrexate in moderate to severe rheumatoid arthritis Aarat M. PatelLarry W. Moreland Clinical Trials Report 06 October 2009 Pages: 313 - 314
Clinical utility of ultrasonography in spondyloarthropathies Roger D. Sturrock OriginalPaper 06 October 2009 Pages: 317 - 320
Diffuse idiopathic skeletal hyperostosis: Differentiation from ankylosing spondylitis Ignazio OlivieriSalvatore D’AngeloMuhammad A. Khan OriginalPaper 06 October 2009 Pages: 321 - 328
New insights into synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome Marina MagreyMuhammad A. Khan OriginalPaper 06 October 2009 Pages: 329 - 333
Clinical assessment and outcome research in spondyloarthritis Robert B. M. LandewéAstrid van Tubergen OriginalPaper 06 October 2009 Pages: 334 - 339
Recent studies on the genetic basis of ankylosing spondylitis John D. Reveille OriginalPaper 06 October 2009 Pages: 340 - 348
Rheumatoid arthritis genetics: 2009 update Robert M. Plenge OriginalPaper 06 October 2009 Pages: 351 - 356
The role of Toll-like receptors in rheumatoid arthritis Qi-Quan HuangRichard M. Pope OriginalPaper 06 October 2009 Pages: 357 - 364
The role of interleukin-17 in the pathogenesis of rheumatoid arthritis Sarah L. Gaffen OriginalPaper 06 October 2009 Pages: 365 - 370
The role of biomarkers in the management of patients with rheumatoid arthritis Jackie NamEdith VilleneuvePaul Emery OriginalPaper 06 October 2009 Pages: 371 - 377
Intracellular signal pathways: Potential for therapies Melissa MaversEric M. RudermanHarris Perlman OriginalPaper 06 October 2009 Pages: 378 - 385